评价NWRD08在HPV16/18阳性宫颈HSIL患者中的安全性和耐受性的 I 期临床研究
[Translation] A Phase I clinical study to evaluate the safety and tolerability of NWRD08 in patients with HPV16/18-positive cervical HSIL
评估NWRD08在宫颈HPV16和/或HPV18阳性HSIL患者中的安全性、耐受性和免疫原性
[Translation] To evaluate the safety, tolerability and immunogenicity of NWRD08 in patients with cervical HPV16 and/or HPV18 positive HSIL
100 Clinical Results associated with Newish Biotechnology (Wuxi) Co., Ltd.
0 Patents (Medical) associated with Newish Biotechnology (Wuxi) Co., Ltd.
100 Deals associated with Newish Biotechnology (Wuxi) Co., Ltd.
100 Translational Medicine associated with Newish Biotechnology (Wuxi) Co., Ltd.